




????????????????


?? ??



I FWER



?? ?????










FWER

FWER




(?) ????







(?) ????????



(?) ??????



FWER



FWER

0.025


0.05

80%


1. ??????



2. ????????



(?) ????????



?? ??????

(?) ????????

1. ???

|

2. ???

FWER

3. ???

4. ???

/

DMC

DMC

DMC

DMC

DMC

(?) ????????

1. ????????

2. ????????

FWER

FWER

P

DMC

DMC

DMC

FWER


1

FWER

2


FWER

I




?? ??

(?) ???????????




(?) ?????????????




FWER


(?) ?????????????



(?) ???????????



(?) ?????????????????



FWER

- | | | |
|------|--|--|
| [1] |  | .  . 2020 |
| [2] |  | .  . 2020 |
| [3] |  | .  . 2022 |
| [4] |  | .  . 2022 |
| [5] |  | .  . 2021 |
| [6] |  | .  . 2021 |
| [7] |  | .  . 2020 |
| [8] |  | .  . 2023 |
| [9] | ICH E1a: The Extent of Population Exposure to Assess Clinical Safety: For Drugs Intended for Long-term Treatment of Non-Life-Threatening Conditions. 1995. | |
| [10] | ICH E8(R1): General Considerations for Clinical Trials. 2022. | |
| [11] | ICH E9: Statistical Principles for Clinical Trials. 1998. | |

[12] [ICH E9\(R1\): Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials](#). 2019.

[13] U.S. Food and Drug Administration. [Adaptive Designs for Clinical Trials of Drugs and Biologics](#). 2019.

Revision #15

Created 2025-11-30 06:26:37 UTC by Colin Wang

Updated 2025-12-15 07:30:52 UTC by Colin Wang